Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Leukemia: Lymphoid leukemia

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 5 - LDE225 for patients with PTCH1 and SMO mutated tumors

Researchers want to know if LDE225 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a PTCH1 and/or SMO activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

The purpose of this study is to find out what effects the combination of ofatumumab and alemtuzumab antibody therapy has on chronic lymphocytic leukemia (CLL).

Status: Accepting New Patients
Principal Investigator: Ma

A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients with Chronic Lymphocytic Leukemia

The purpose of this study is to see whether or not a new type of vaccine might be safe and effective in the treatment of patients who have CLL but do not meet criteria for standard forms of treatment.

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the effects, both good and bad, that two different cancer treatments have on patients and their cancer. These treatments include combinations of the drugs rituximab, fludarabine, cyclophosphamide and ibrutinib.

Status: Accepting New Patients
Principal Investigator: Ma

A Randomized Phase III Study Of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (= 65 Years Of Age) with Chronic Lymphocytic Leukemia (CLL)

The purpose of this study is to compare the safety (side effects) and effectiveness of the research drug ibrutinib to the standard treatment for your disease.

Status: Accepting New Patients
Principal Investigator: Ma

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 3 - MEK162 for Patients with RAS/RAF/MEK Activated Tumors Local

The purpose of this clinical trial is to study if MEK162 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a RAS/RAF/MEK activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFC600 Mutated Tumors

Researchers want to know if LGX818 is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with a BRAFV600 activated pathway. This pathway is thought to play a role in tumor cell growth as well as in the growth of new blood vessels, which supply the tumor with nutrients and oxygen.

Status: Accepting New Patients
Principal Investigator: Johnson

Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 2 - Dovitinib for Patients with Tumor Pathway Activations Inhibited by Dovitinib Including Tumors with Mutations or Translocations of FGFR, PDGFR, VEGF, CKIT, FLT3, CSFR1, TRK and RET

Researchers want to know if dovitinib (TKI258) is safe and has beneficial effects in people who have different tumor types (cancer) and/or blood malignancies whose disease progressed after standard treatment.

Status: Accepting New Patients
Principal Investigator: Johnson

A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Relapsed and/or Treatment-Refractory Leukemia

The purpose of this study is to evaluate the safety of an investigational drug, CB-839, and to determine the best dose to use for future studies.

Status: Accepting New Patients
Principal Investigator: Frankfurt

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients with CD30+ and/or EBV+ Lymphomas

The purpose of this study is to evaluate how safe and effective the combination of two different drugs (brentuximab vedotin and rituximab) is in patients with certain types of lymphoma.

Status: Accepting New Patients
Principal Investigator: Petrich

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Hitsman

Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator’s Choice in Subjects with Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

The main purpose of this study is to determine if KW-0761, an investigational drug (has not been approved by the U.S. food and Drug Administration [FDA]), will work against adult T-cell leukemia-lymphoma (ATL)that has failed to respond to other treatments, and to evaluate its side effects.

Status: Accepting New Patients
Principal Investigator: Petrich

A Phase 2 Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

The purpose of a phase 2 study is to determine the efficacy, safety and tolerability of intravenous bortezomib in patients with pulmonary GVHD after allogeneic HSCT.

Status: Accepting New Patients
Principal Investigator: Jain

A Phase 1, Open-Label, Dose Escalation and Expanded Cohort, Continuous Intravenous Infusion, Multicenter Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EPZ-5676 in Treatment Relapsed/Refractory Patients with Leukemias Involving Translocations of the MLL Gene at 11q23 or Advanced Hematologic Malignancies

The purpose of this study is to find out the effects, good and bad, that EPZ-5676 has on patients and their cancer.

Status: Accepting New Patients
Principal Investigator: Altman

An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator’s Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

The main purpose of this study is to learn if inotuzumab ozogamicin (study drug) is more effective treating relapsed (disease came back after responding to a previous treatment) or refractory (disease did not respond to previous treatment) CD22-positive acute lymphoblastic leukemia (ALL) than other standard chemotherapy treatments.

Status: Accepting New Patients
Principal Investigator: Frankfurt

CALGB 10701: A Phase II Study of Dasatinib (Sprycel®) (Ind #73969, Nsc #732517) as Primary Therapy Followed by Transplantation for Adults = 18 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG

The purpose of this study is find out what effects (good and/or bad)dasatinib has when administered in combination with standard chemotherapy on acute lymphoblastic leukemia (ALL).

Status: Accepting New Patients
Principal Investigator: Frankfurt

Randomized Placebo Controlled Double-Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation

The purpose of this study is to see how effective Restasis is in the prevention of ocular graft-versus-host disease (GVHD).

Status: Accepting New Patients
Principal Investigator: Basti

last updated: Wed - September 17, 2014 - 04:26 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.